Sinclair Pharma licenses Decapinol rights

By Elaine Rigoli

Tampa, Fla., June 29 - Sinclair Pharma plc has licensed the exclusive U.S. rights of one of its key products, Decapinol, to OraPharma, Inc., a subsidiary of Johnson & Johnson.

Under the terms of the deal, Sinclair will supply Decapinol to OraPharma, which will be responsible for the marketing and distribution of the product in the U.S. market.

Sinclair will receive up-front and milestone payments and a margin on product sales. Sales are expected to start within the next 12 months.

Decapinol has a new mode of action for the treatment of gingivitis (gum inflammation) and dental plaque and for the prevention of periodontitis (a severe form of gum disease causing tooth loss), according to a news release.

With about 80% of the adult population in the United States estimated to have some degree of gum inflammation, Decapinol oral rinse may address a growing market currently exceeding $600 million, the release said.

Sinclair Pharma, based in Godalming, U.K., is an international specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.